Recursion Pharmaceuticals Receives Fast-Track SBIR Grant to Study Age-Related Disease
Recursion Pharmaceuticals, an exciting biotech company located in the University of Utah’s Research Park, today announced a $223,000 Phase I Small Business Innovation Research award from the National Institutes of Health (NIH) via the National Institute on Aging (NIA). The award, which has... - September 15, 2016
Recursion Pharmaceuticals Supports White House Precision Medicine Initiative
Recursion Pharmaceuticals today announced that it is part of a group of nationally recognized private and public institutions making commitments as part of President Obama's Precision Medicine Initiative to rapidly find new treatments for ultra-rare genetic diseases. - February 25, 2016
Recursion Pharmaceuticals Receives $2.6 Million in Follow-on Seed Funding
Funding will be used to accelerate and scale the company’s proprietary drug discovery platform. - December 08, 2015
Recursion Pharma Receives Orphan Drug Designation for Hereditary Stroke Disorder
Recursion Pharmaceuticals, a drug discovery start-up company, announced receipt of an Orphan Drug Designation from the FDA for the use of Tempol for the treatment of Cerebral Cavernous Malformation, a hereditary stroke disease. Recursion expects this will be the first of many potential treatments identified using their proprietary drug discovery platform. - October 05, 2015
H. Perry Fell, Experienced BioTech Executive, Joins Board of Recursion Pharmaceuticals
H. Perry Fell, past CEO of Seattle Genetics and NanoString, joins the Board of Recursion Pharmaceuticals. Recursion is an emerging biotech company seeking to combine the best elements of computation and functional genetics to rapidly identify novel therapeutic opportunities for genetic diseases. - May 27, 2015
Recursion Pharmaceuticals Announces Funding Support for Ataxia-Telangiectasia
Recursion today announced a grant from the AT-Children's Project to advance it's innovative drug discovery work towards identifying novel treatments for ataxia-telangiectasia, a brutal childhood genetic disease. - March 20, 2015
Recursion Pharmaceuticals Announces Funding for Rett Syndrome Research
Recursion Pharmaceuticals has received support for focused work to identify a treatment for Rett Syndrome by the Rett Syndrome Research Trust. Recursion will apply its innovative drug discovery platform immediately to investigate the gene MECP2 in an effort to identify new therapeutics for the condition. - July 09, 2014
Recursion Pharmaceuticals Announces Dr. H. Perry Fell as the First Member of Business Advisory Panel
Recursion Pharmaceuticals, a biotech start-up in Salt Lake City today announced the formation of its Business Advisory Panel. The first appointment to the Advisory Panel is H. Perry Fell, MBA, Ph.D. Perry is a distinguished scientist and leader who most prominently co-founded Seattle Genetics (NASDAQ: SGEN) and served as its CEO from start-up through IPO. - June 05, 2014
Recursion Pharmaceuticals Announces Formation of Its Scientific and Technical Advisory Board
Recursion Pharmaceuticals is a start-up biotech firm in Salt Lake City with a goal of discovering new therapeutics for the treatment of rare genetic diseases. Recursion announced the formation of its Scientific and Technical Advisory Board today, along with the appointment of Dr. Anne Carpenter and Dr. Kirk Thomas as its first two members. - April 12, 2014